Kilitch Drugs (India) 過去の業績
過去 基準チェック /36
Kilitch Drugs (India)は、平均年間46.6%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間13.4% 24.3%収益成長率で 成長しています。 Kilitch Drugs (India)の自己資本利益率は7.5%であり、純利益率は10.4%です。
主要情報
46.6%
収益成長率
46.0%
EPS成長率
| Pharmaceuticals 業界の成長 | 17.5% |
| 収益成長率 | 24.3% |
| 株主資本利益率 | 7.5% |
| ネット・マージン | 10.4% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar
Jul 23
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16収支内訳
収支内訳
Kilitch Drugs (India) の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 1,575 | 165 | 281 | 0 |
| 30 Jun 24 | 1,513 | 126 | 252 | 0 |
| 31 Mar 24 | 1,544 | 146 | 240 | 0 |
| 31 Dec 23 | 1,550 | 146 | 243 | 0 |
| 30 Sep 23 | 1,532 | 140 | 240 | 0 |
| 30 Jun 23 | 1,427 | 117 | 238 | 0 |
| 31 Mar 23 | 1,396 | 104 | 232 | 0 |
| 31 Dec 22 | 1,307 | 98 | 178 | 0 |
| 30 Sep 22 | 1,352 | 85 | 154 | 0 |
| 30 Jun 22 | 1,281 | 83 | 133 | 0 |
| 31 Mar 22 | 1,142 | 74 | 117 | 0 |
| 31 Dec 21 | 976 | 52 | 132 | 0 |
| 30 Sep 21 | 835 | 63 | 126 | 0 |
| 30 Jun 21 | 780 | 62 | 110 | 0 |
| 31 Mar 21 | 685 | 37 | 97 | 0 |
| 31 Dec 20 | 602 | 17 | 89 | 0 |
| 30 Sep 20 | 558 | 4 | 91 | 0 |
| 30 Jun 20 | 531 | -3 | 92 | 0 |
| 31 Mar 20 | 533 | 8 | 114 | 0 |
| 31 Dec 19 | 609 | 26 | 103 | 0 |
| 30 Sep 19 | 534 | -32 | 111 | 0 |
| 30 Jun 19 | 648 | -3 | 127 | 0 |
| 31 Mar 19 | 825 | 38 | 159 | 0 |
| 31 Mar 18 | 510 | 52 | 77 | 0 |
| 31 Mar 17 | 287 | -89 | 172 | 0 |
| 31 Mar 16 | 210 | -112 | 155 | 0 |
| 31 Mar 15 | 190 | -3 | 129 | 0 |
| 31 Dec 14 | 222 | -8 | 94 | 0 |
| 30 Sep 14 | 199 | 8 | 97 | 0 |
| 30 Jun 14 | 168 | -1 | 93 | 0 |
| 31 Mar 14 | 149 | 12 | 87 | 0 |
| 31 Dec 13 | 151 | 35 | 51 | 0 |
質の高い収益: KILITCHは 高品質の収益 を持っています。
利益率の向上: KILITCHの現在の純利益率 (10.4%)は、昨年(9.2%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: KILITCH過去 5 年間で収益を上げており、収益は年間46.6%増加しています。
成長の加速: KILITCHの過去 1 年間の収益成長率 ( 17.3% ) は、5 年間の平均 ( 年間46.6%を下回っています。
収益対業界: KILITCHの過去 1 年間の収益成長率 ( 17.3% ) Pharmaceuticals業界20.5%を上回りませんでした。
株主資本利益率
高いROE: KILITCHの 自己資本利益率 ( 7.5% ) は 低い とみなされます。